GlaxoSmithKline’s interest in using digital health tools to quantify the effectiveness of its medications is growing. It will enlist Owlstone Medical’s breath analysis tool ReCIVA Breath Sampler in a Phase 2 clinical trial for chronic obstructive pulmonary disease, according to a company press release.
The study will seek to determine whether Owlstone Medical’s breath biospy tool can match the right patient for the right treatment and to assess the treatment effects of a novel drug for COPD.
The ReCIVA Breath Sampler relies on Field Asymmetric Ion Mobility Spectrometer (FAIMS) chips to detect the traces of specific chemicals. Although Owlstone Medical’s focus has been on using its technology to detect cancer earlier, Boyle has said that the company is also keen to find other conditions well suited for deploying its technology.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Owlstone Medical is a spinoff of Owlstone and focuses on medical diagnostics. In an interview last year, Owlstone Medical Cofounder and CEO Billy Boyle likened the company’s technology to a mass spectrometer on a silicon chip.
“The thing that makes the technology unique is that you can program what you’re trying to detect just by changing the software,” Boyle said in the interview.
In a statement about the GSK partnership, Boyle said that the company plans to work with other pharma partners to assess “the health economic impact of their new medicines across a broad range of diseases by providing access to the data needed to ensure that the right therapy is given to the right patient at the right time.”
GSK worked with Propeller Health to secure FDA approval for the use of the company’s smart inhaler tracking tool with GSK’s Ellipta inhaler to quantify adherence and effectiveness for respiratory disease treatments.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Photo: Nasco, Getty Images
